We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
- Authors
Brufsky, Adam M; Hurvitz, Sara; Perez, Edith; Swamy, Raji; Valero, Vicente; O'Neill, Vincent; Rugo, Hope S
- Abstract
This phase III study compared the efficacy and safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone as second-line treatment of patients with human epidermal growth factor receptor 2 (HER2) -negative metastatic breast cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 32, p4286
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.34.1255